Stock Performance Review on Biotech Industry -- Ardelyx, Bellicum Pharma, Iovance Biotherapeutics, and Inotek Pharma

Thursday, November 16, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 16, 2017 /PRNewswire/ -- If you want a Stock

Review on ARDX, BLCM, IOVA, or ITEK then come over to and sign up for your free customized report. On Wednesday, the NASDAQ Composite ended the day at 6,706.21, down 0.47%; the Dow Jones Industrial Average
edged 0.59% lower, to finish at 23,271.28; and the S&P 500 closed at 2,564.62, marginally slipping 0.55%. Losses were broad based as all sectors finished the trading session in red. has initiated research reports on the following Biotechnology stocks: Ardelyx Inc. (NASDAQ: ARDX), Bellicum Pharmaceuticals Inc. (NASDAQ: BLCM), Iovance Biotherapeutics Inc. (NASDAQ: IOVA), and Inotek Pharmaceuticals Corp. (NASDAQ: ITEK). Daily Stock Tracker published comprehensive and free research reports on these stocks today at:


Fremont, California headquartered Ardelyx Inc.'s stock finished Wednesday's session 0.95% higherat $5.30 with a total trading volume of 273,848 shares. The stock has gained 19.10% over the past three months. Shares of the Company are trading belowtheir 50-day moving average by 5.42%. Moreover, shares of Ardelyx, which develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the US,have a Relative Strength Index (RSI) of 45.52.

On October 17th, 2017, research firm Leerink Partners resumed its 'Outperform' rating on the Company's stock. ARDX complete research report is just a click away and free at:

Bellicum Pharmaceuticals

Shares in Houston, Texas headquartered Bellicum Pharmaceuticals Inc. rose 1.06%, ending yesterday's session at $9.50 with a total trading volume of 338,550 shares. The stock has gained 24.67% in the previous three months. The Company's shares are trading belowtheir 50-day moving average by 11.08%. Moreover, shares of Bellicum Pharma, which focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the US and internationally, have an RSI of 38.25. The complimentary report on BLCM can be downloaded at:

Iovance Biotherapeutics

On Wednesday, San Carlos, California headquarteredIovance Biotherapeutics Inc.'s stock saw a rise of 1.94%, to close the day at $7.90. A total volume of 371,362 shares was traded. The Company's shares have advanced 69.89% in the previous three months and 13.67% on an YTD basis. The stock is trading aboveits 50-day and 200-day moving averages by 4.93% and 17.02%, respectively. Additionally, shares of Iovance Biotherapeutics, which focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells,have an RSI of 53.59.

On November 01st, 2017, research firm B. Riley FBR, Inc. reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $17.50 a share to $18 a share. Sign up for your complimentary research report on IOVA at:

Inotek Pharmaceuticals

Shares in Lexington, Massachusetts headquarteredInotek Pharmaceuticals Corp. ended the day 1.22% lowerat $2.42. A total volume of 487,636 shares was traded. The stock has gained 154.71% in the previous three months. The Company's shares are trading abovetheir 50-day and 200-day moving averages by 15.38% and 42.14%, respectively. Furthermore, shares of Inotek Pharma, which focuses on the discovery, development, and commercialization of therapies for glaucoma and other diseases of the eye in the US,have an RSI of 51.11. Get free access to your research report on ITEK at:

Daily Stock Tracker:

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: Phone number: (207)331-3313Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


View original content:


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store